Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox
A D
AD
University of North Carolina at Chapel Hill, Department of Radiation Oncology, 27599, USA. cox@radonc.unc.edu
Der
C J
CJ
D019883:Alkyl and Aryl Transferases; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle; D002460:Cell Line / Q000187:drug effects; D002461:Cell Line, Transformed / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D015195:Drug Design; D051231:Farnesyltranstransferase; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D017368:Protein Prenylation / Q000187:drug effects; D014166:Transferases / Q000037:antagonists & inhibitors*; D018631:ras Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology
D000970:Antineoplastic Agents; D014166:Transferases; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D018631:ras Proteins